The Vanguard Group 13D and 13G filings for BioCryst Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-07 10:52 am Purchase |
2024-10-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
The Vanguard Group | 20,730,939 10.020% |
424,343 (+2.09%) |
Filing |
| 2024-11-07 10:25 am Unchanged |
2024-09-30 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
The Vanguard Group | 20,306,596 9.810% |
0 (Unchanged) |
Filing |
| 2024-11-04 11:18 am Purchase |
2024-09-30 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
The Vanguard Group | 20,306,596 9.810% |
2,542,876 (+14.31%) |
Filing |
| 2024-02-13 5:00 pm Purchase |
2023-12-29 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
The Vanguard Group | 17,763,720 8.670% |
3,559,325 (+25.06%) |
Filing |
| 2023-02-09 11:12 am Purchase |
2022-12-30 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
The Vanguard Group | 14,204,395 7.620% |
4,791,490 (+50.90%) |
Filing |
| 2022-02-09 3:33 pm Sale |
2021-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
The Vanguard Group | 9,412,905 5.230% |
-2,186,429 (-18.85%) |
Filing |
| 2021-02-10 10:39 am Purchase |
2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
The Vanguard Group | 11,599,334 6.570% |
3,477,703 (+42.82%) |
Filing |